cetuximab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mucinous Gastrointestinal Adenocarcinoma

Conditions

Mucinous Gastrointestinal Adenocarcinoma

Trial Timeline

Nov 1, 2004 → Jan 1, 2007

NCT ID

NCT00162110

About cetuximab

cetuximab is a phase 2 stage product being developed by Eli Lilly for Mucinous Gastrointestinal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00162110. Target conditions include Mucinous Gastrointestinal Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00698841	Phase 2	Completed	Feb 1, 2009	Feb 1, 2010	Advanced Cancer
NCT00292955	Phase 2	UNKNOWN	Feb 1, 2006	—	Cancer of the Cervix
NCT00362102	Phase 2	Completed	Oct 1, 2005	Jul 1, 2006	Colorectal Carcinoma
NCT00207116	Phase 1	Completed	Sep 1, 2005	Mar 1, 2006	Carcinoma, Non-Small-Cell Lung
NCT00082212	Phase 2	Terminated	Nov 1, 2004	Jun 1, 2007	Ovarian Cancer
NCT00162110	Phase 2	Completed	Nov 1, 2004	Jan 1, 2007	Mucinous Gastrointestinal Adenocarcinoma
NCT00083720	Phase 2	Completed	Oct 1, 2004	Apr 1, 2008	Colorectal Neoplasms
NCT00207155	Phase 1	Completed	Dec 1, 2003	Feb 1, 2006	Metastatic Colorectal Cancer
NCT00063388	Phase 2	Completed	May 1, 2003	Jun 1, 2005	Non-Small-Cell Lung Cancer
NCT00055419	Phase 2	Completed	Feb 1, 2003	Aug 1, 2004	Colorectal Neoplasms

Competing Products

2 competing products in Mucinous Gastrointestinal Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
panitumumab + irinotecan hydrochloride + fluorouracil + leucovorin calcium	Amgen	Phase 2	35
aflibercept + oxaliplatin + leucovorin + fluorouracil	Sanofi	Phase 2	35